BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells | Zendy

Ali Alhoshani | Zendy; Fahad O. Alatawi | Zendy; Fawaz E. Alanazi | Zendy; Ibraheem M. Attafi | Zendy; Asad Zeidan | Zendy; Abdelali Agouni | Zendy; Heba M. El Gamal | Zendy; Licia Shamoon | Zendy; Sarah Khalaf | Zendy; Hesham M. Korashy | Zendy

Open Access

BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells

Author(s) -

Ali Alhoshani,

Fahad O. Alatawi,

Fawaz E. Alanazi,

Ibraheem M. Attafi,

Asad Zeidan,

Abdelali Agouni,

Heba M. El Gamal,

Licia Shamoon,

Sarah Khalaf,

Hesham M. Korashy

Publication year - 2020

Publication title -

oncotargets and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.054

H-Index - 60

ISSN - 1178-6930

DOI - 10.2147/ott.s281519

Subject(s) - apoptosis , cell cycle , cancer research , cell cycle checkpoint , autophagy , cell growth , cyclin d1 , venetoclax , cancer , cancer cell , programmed cell death , breast cancer , g1 phase , chemistry , biology , microbiology and biotechnology , medicine , leukemia , immunology , biochemistry , chronic lymphocytic leukemia

Venetoclax (VCX) is a selective BCL-2 inhibitor approved for the treatment of leukemia and lymphoma. However, the mechanisms of anti-cancer effect of VCX either as a monotherapy or in combination with other chemotherapeutic agents against breast cancer need investigation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research